Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $1.71 0.2800 +19.58%
ZIOP $3.24 0.4400 +15.71%
FATE $4.62 0.3900 +9.22%
TGTX $10.89 0.8400 +8.36%
ADXS $3.33 0.2500 +8.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $8.75 -0.4700 -5.10%
AVEO $0.97 -0.0500 -4.90%
CVM $0.66 -0.0299 -4.33%
CERU $3.96 -0.1600 -3.88%
CYTR $2.80 -0.1100 -3.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Press Release: New Affordable Care Act Initiative to Support Care Coordination Nationwide

( Oct 15, 2014 - The Centers for Medicare & Medicaid Services (CMS) today announced the availability of a new initiative for Accountable Care Organizations (ACOs) participating in the Medicare Shared Savings Program.
read press release 

Novartis Psoriasis Drug Benefits Outweighs Risk: FDA Staff

(Reuters) Oct 16, 2014 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.
read article 

New Breast Cancer Drugs Boost Sales at Roche

(Reuters) Oct 16, 2014 - Swiss drugs firm Roche reported better than expected third-quarter sales on Thursday, boosted by a strong performance from its new breast cancer drugs.
read article 

Roche, Boehringer Drugs Wins Approval For Lung Disease

(Bloomberg) Oct 16, 2014 - Roche Holding AG and Boehringer Ingelheim GmbH won approval for the first therapies in the U.S. to treat the deadly lung disease idiopathic pulmonary fibrosis.
read article 

Blue Ridge Cancer Care Adds New Medical Oncologist to Roanoke Facility, Enhancing Timely Access to Quality Care

(Yahoo! Finance) Oct 16, 2014 - Blue Ridge Cancer Care (BRCC), the leading cancer care provider serving Southwest Virginia for more than 35 years and an affiliate of The US Oncology Network, has added another medical oncologist to its staff, enhancing care to patients in the Roanoke area.
read article 

Researchers Will Study Relation of Environment to Breast Cancer

(Boston Globe) Oct 16, 2014 - A consortium of five eminent Boston researchers will officially join forces Thursday to tackle one of the most perplexing questions about breast cancer: Why do so many people with no family history of the disease develop it?
read article (free registration required) 

Nanobiotix Gets French Go Ahead For Pivotal Study of Its Breakthrough Cancer Treatment

(Proactive Investors UK) Oct 16, 2014 - Nanobiotix said it has received approval from French regulators to embark on phase II/III registration of its lead product.
read article 

Rare-Cancer R&D: Patients Are Willing to Take Risks, EMA Told

(PharmaTimes [UK]) Oct 15, 2014 - The European Medicines Agency says it is open to discussing the use of complementary evidence sources and methodologies with developers of potential treatments for rare cancers, for which large-scale clinical trials are frequently impossible.
read article 

Experimental Lung Cancer Vaccine Lands Berkeley Company Potential $817M Deal

(San Francisco Business Times) Oct 16, 2014 - Tiny Aduro BioTech Inc.’s experimental cancer vaccine has come up big again, landing a potential $817 million deal with Johnson & Johnson’s Janssen Biotech unit around lung cancer, the companies said Thursday.
read article 

Maine Hospitals See Price Increase For Specialty Cancer Drugs

(Maine Public Broadcasting [Bangor, ME]) Oct 15, 2014 - A new change in the way three of the most commonly used cancer drugs are distributed could cause new headaches for hospitals and their patients.
read article 

Two-Faced Gene: SIRT6 Prevents Some Cancers But Promotes Sun-Induced Skin Cancer

(University of Chicago Medicine) Oct 15, 2014 - A new study published in Cancer Research shows SIRT6 -- a protein known to inhibit the growth of liver and colon cancers -- can promote the development of skin cancers by turning on an enzyme that increases inflammation, proliferation and survival of sun-damaged skin cells.
read press release 

Can Low-T Therapy Promote Prostate Cancer?

(TIME) Oct 15, 2014 - “Low T” therapy is a fast-growing trend for men who want to jack up testosterone—which declines naturally with age but which can also be clinically low in some people—and the testosterone therapy industry is predicted to reach $5 billion by 2017.
read article 

In Some Men, an Increase in PSA After Prostate Cancer Surgery May Not Lead to Metastasis in Their Lifetime

(AACR) Oct 15, 2014 - Some prostate cancer patients whose prostate-specific antigen (PSA) levels increase after a radical prostatectomy may die of causes unrelated to prostate cancer before they are diagnosed with a prostate cancer metastasis, and therefore treating them for recurrence may not be beneficial, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
read press release 

Side Effects of Cancer Prevention Surgery Can Be Helped With a Single-Day Education Program, Study Finds

(Dana-Farber) Oct 14, 2014 - More women are having ovary-removing surgery as a cancer prevention measure, but many are often unaware of sexual or psychological side effects of the procedure.
read press release 

New Test Can Help Doctors Choose Best Treatment For Ovarian Cancer

(Imperial College London [UK]) Oct 16, 2014 - Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
read article 

Use of Intensive Medical Services For Ovarian Cancer Patients at End of Life Increases Despite Rise in Use of Hospice

(Dana-Farber) Oct 15, 2014 - As more terminaly ill patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A new study shows that for one group of terminally ill cancer patients, that is not the case.
read press release 

Dendreon's Provenge Too Expensive For NHS Use, Says NICE

(PharmaTimes [UK]) Oct 16, 2014 - Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer on the National Health Service in England, cost regulators have ruled.
read article 

T-Cell Therapy Puts Leukemia Patients in Extended Remission

(New York Times) Oct 15, 2014 - An experimental therapy has brought prolonged remissions to a high proportion of patients who were facing death from advanced leukemia after standard treatments had failed, researchers are reporting.
read article 

Novartis Leukemia Treatment Yields High Remission Rate

(Bloomberg) Oct 15, 2014 - A new leukemia immune treatment being developed by Novartis AG led to the disappearance of cancer in 90 percent of patients, a study showed.
read article 

MD Anderson Study First to Compare Treatments, Survival Benefits for Early-Stage Lung Cancer

(MD Anderson) Oct 15, 2014 - Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center.
read press release 

Cost to NHS of Providing Sipuleucel-T Too High to Be Recommended in Draft Guidance

(NICE) Oct 16, 2014 - NICE has issued preliminary draft guidance not recommending sipuleucel-T for prostate cancer in people whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given.
read press release 

U.S. Top Court Hears Teva's Multiple Sclerosis Drug Patent Fight

(Reuters) Oct 15, 2014 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.
read article 

U.S. Inversion Rules Cloud AbbVie-Shire Deal

(USA Today) Oct 15, 2014 - Faced with tougher Treasury rules on corporate mergers that are aimed at cutting U.S. tax bills, biopharmaceutical company AbbVie is reconsidering a nearly $55 billion deal with Ireland's Shire Pharmaceuticals.
read article 

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

(TheStreet) Oct 15, 2014 - There's a robust debate among investors around the ability of Seattle Genetics to move up Adcetris into the front-line treatment setting for Hodgkin's lymphoma.
read article 

November 6, 2014: Oncologic Drugs Advisory Committee Meeting Announcement (Updated Information)

( Oct 14, 2014 - Agenda: During the morning session, the committee will discuss New Drug Application (NDA) 205353, panobinostat capsules, application submitted by Novartis Pharmaceuticals Corporation.
read article